Overview

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Alendronate